Chinese Journal of Cancer Research

, Volume 20, Issue 2, pp 77–84

Anti-tumor action and clinical application of proteasome inhibitor

  • Yong-ming Zhou周咏明
  • Mei-xia Yu余美霞
  • Hui Long龙辉
  • Shi-ang Huang黄士昂
Review

DOI: 10.1007/s11670-008-0077-1

Cite this article as:
Zhou, Y., Yu, M., Long, H. et al. Chin. J. Cancer Res. (2008) 20: 77. doi:10.1007/s11670-008-0077-1

Abstract

Ubiquitin-proteasome pathway mediates the degradation of cell protein, and cell cycle, gene translation and expression, antigen presentation and inflammatory development. Proteasome inhibitor can inhibit growth and proliferation of tumor cell, induce apoptosis and reverse multipledrug resistance of tumor cell, increase the sensitivity of other chemotherapeutic drugs and radiotherapy, and is a novel class of potent anti-tumor agents.

Key words

Proteasome inhibitorUbiquitin-proteasome pathwayTumor

CLC number

R963

Copyright information

© Chinese Anti-Cancer Association and Springer-Verlag GmbH 2008

Authors and Affiliations

  • Yong-ming Zhou周咏明
    • 1
  • Mei-xia Yu余美霞
    • 1
  • Hui Long龙辉
    • 1
  • Shi-ang Huang黄士昂
    • 2
  1. 1.Department of hematology, The Affiliated HospitalWuhan University of Science and TechnologyWuhanChina
  2. 2.Stem Cell Center, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina